The European Commission has approved Sepalna (senaparib) as a monotherapy maintenance treatment for adults with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer whose disease has responded either completely or partially following first-line platinum-based chemotherapy.
The approval covers patients with FIGO stage 3 and 4 disease and follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in September 2026. The decision, granted on 12 November 2026, marks a significant regulatory milestone for the treatment in Europe.
Pharmanovia and IMPACT Therapeutics announced the authorisation, which applies across the European Union. Pharmanovia holds exclusive regional development and commercialisation rights for senaparib across 66 countries, including the UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and countries in the Middle East and North Africa.
Senaparib, developed by IMPACT Therapeutics, is a targeted anti-cancer therapy. The approval was supported by evidence from the phase 3 FLAMES study, a randomised, double-blind, placebo-controlled trial involving patients with newly diagnosed advanced ovarian cancer responding to first-line platinum-based chemotherapy, regardless of BRCA mutation status.
At a median follow-up of 48.5 months, the study showed median progression-free survival of 38.7 months in patients receiving senaparib compared with 13.6 months in the placebo group. Benefits were observed in both BRCA-mutated and BRCA wild-type patient populations.
Updated safety data from 403 patients showed that 5.6% of those treated with senaparib discontinued treatment because of treatment-emergent adverse events. The most common adverse events included anaemia, neutropenia, leukopenia, thrombocytopenia, increased transaminases, weight gain, nausea and abdominal pain.
No treatment-emergent adverse events resulted in death.
Stephan Eder, Chief Executive Officer of Pharmanovia, said: “The European Commission’s approval of Sepalna represents an important milestone for patients with advanced ovarian cancer and for our growing oncology portfolio.”
He added: “We congratulate our partner IMPACT Therapeutics on this significant achievement, reflecting years of dedicated research and clinical development.”
Eder continued: “Our focus at Pharmanovia is now on preparing for the introduction of Sepalna across Europe and working towards making this treatment available to eligible patients.”










